# Eagle Pharmaceuticals, Inc. (EGRX)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/EGRX/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2023 | $ 141.59M | $ 11.80M | $ -36.44M | $ 71.62M | $ 252.04M |
| 2022 | $ 353.69M | $ 43.86M | $ 56.44M | $ 62.47M | $ 233.56M |
| 2021 | $ 203.91M | $ -10.25M | $ 33.16M | $ 25.61M | $ 176.45M |
| 2020 | $ 239.25M | $ 15.27M | $ 62.10M | $ 37.09M | $ 186.01M |
| 2019 | $ 252.85M | $ 18.47M | $ 71.26M | $ 38.56M | $ 179.17M |
| 2018 | $ 281.72M | $ 42.14M | $ 69.01M | $ 44.41M | $ 160.76M |
| 2017 | $ 318.88M | $ 69.97M | $ 72.39M | $ 47.78M | $ 179.14M |
| 2016 | $ 260.70M | $ 112.07M | $ 44.74M | $ 0 | $ 151.23M |
| 2015 | $ 92.99M | $ 3.61M | $ -16.29M | $ 0 | $ 90.34M |
| 2014 | $ 27.14M | $ -28.58M | $ -30.79M | $ 0 | $ 27.91M |
| 2013 | $ 25.16M | $ -9.70M | $ -5.82M | $ 0 | $ 774.7K |
| 2012 | $ 4.03M | $ -11.09M | $ -10.78M | $ 0 | $ -11.44M |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | 0.28 |
| Liabilities / Eq | 0.61 |
| Current Ratio | 2.16 |

## Debt coverage

| Indicator | Value |
| --- | --- |
| Gross Debt / Earnings | 2.61 |
| Gross Debt / FCF | 2.20 |

## Other views

- [Metrics](https://sponda.capital/en/EGRX.md)
- [Charts](https://sponda.capital/en/EGRX/charts.md)
- [Compare](https://sponda.capital/en/EGRX/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-27.